BioCryst Pharmaceuticals, Inc. (BCRX) analyst actions
Rating and price-target actions on BCRX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BCRX overview →
2 measured BCRX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) | Press release | -1.36% | -0.29% | |
| BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat) | Press release | +0.20% | +3.89% |
Keep exploring
More BCRX: earnings → · SEC filings → · BCRX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CORIUM INTL (CORI) | 380 | 0.00% | 46% |
| PROTEON THERAPEUTICS (PRTO) | 380 | 0.00% | 39% |
| Constellation Pharmaceuticals, Inc (CNST) | 379 | 0.00% | 44% |
| CONTRAVIR PHARMACEUTICALS INC (CTRV) | 379 | -0.51% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.